利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

79 条记录 (耗时 0.029 秒)

    ENTERIC COATED TABLET
    12.
    发明申请
    ENTERIC COATED TABLET 有权

    公开(公告)号：US20210093577A1

    公开(公告)日：2021-04-01

    申请号：US17118824

    申请日：2020-12-11

    申请人： ZERIA PHARMACEUTICAL CO., LTD.

    发明人： Akio RYU ,  Miyako OSADA

    IPC分类号： A61K9/28 ,  A61K31/606

    摘要： To provide an enteric coated tablet containing a large amount of medicinal ingredient and having sufficient impact resistance, without forming a thick enteric coating layer.
    The enteric coated tablet contains (A) a core tablet containing a medicinal ingredient and having a weight of 1,000 mg or more; (B) a coating layer containing a water-soluble polymer applied onto the surface of the core tablet; and (C) an enteric coating layer dissolving at pH 7 or higher which is applied onto the surface of the coating layer containing a water-soluble polymer, wherein the sum of the polymer amount of the coating layer (B) and the polymer amount of the coating layer (C) is 10 to 18 mg/cm2, the polymer amount of the coating layer (B) is 6 to 12 mg/cm2, and the polymer amount of the coating layer (C) is 3 to 6 mg/cm2.

    ENTERIC COATED TABLET
    13.
    发明申请
    ENTERIC COATED TABLET 审中-公开

    公开(公告)号：US20190015345A1

    公开(公告)日：2019-01-17

    申请号：US16136377

    申请日：2018-09-20

    申请人： ZERIA PHARMACEUTICAL CO., LTD.

    发明人： Akio Ryu ,  Miyako Osada

    IPC分类号： A61K9/28 ,  A61K31/606

    摘要： To provide an enteric coated tablet containing a large amount of medicinal ingredient and having sufficient impact resistance, without forming a thick enteric coating layer.The enteric coated tablet contains (A) a core tablet containing a medicinal ingredient and having a weight of 1,000 mg or more; (B) a coating layer containing a water-soluble polymer applied onto the surface of the core tablet; and (C) an enteric coating layer dissolving at pH 7 or higher which is applied onto the surface of the coating layer containing a water-soluble polymer, wherein the sum of the polymer amount of the coating layer (B) and the polymer amount of the coating layer (C) is 10 to 18 mg/cm2, the polymer amount of the coating layer (B) is 6 to 12 mg/cm2, and the polymer amount of the coating layer (C) is 3 to 6 mg/cm2.

    Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof
    18.
    发明授权
    Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof 有权
    咔唑衍生物，其溶剂化物或其药学上可接受的盐

    公开(公告)号：US08329913B2

    公开(公告)日：2012-12-11

    申请号：US11666631

    申请日：2005-10-28

    申请人： Masakazu Murata ,  Yoshihiko Itokazu ,  Ryu Nakao

    发明人： Masakazu Murata ,  Yoshihiko Itokazu ,  Ryu Nakao

    IPC分类号： C07D293/00

    CPC分类号： C07D413/12 ,  C07D413/14 ,  C07D417/12

    摘要： An object of the present invention is to provide novel carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof having an excellent adipose tissue weight reducing effect, hypoglycemic effect, and hypolipidemic effect, which are useful as a preventive and/or therapeutic agent for fatty liver, obesity, lipid metabolism abnormality, visceral adiposity, diabetes, hyperlipemia, impaired glucose tolerance, hypertension, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and the like.The above-mentioned object can be achieved by carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof, wherein the carbazole derivatives are represented by the following general formula (I): (In the formula (I), the ring A represents phenyl group or the like; X represents —O— or the like; Y represents ═N— or the like; a and b represent methylene group or the like; both V and Z represent —O— or the like; W represents a C1-C10 alkylene group whose 1 or 2 hydrogen atoms may be substituted by a phenyl group or a C1-C6 alkyl group; 1,2-phenylene group; 1,3-cyclohexyl group; or the like; R1 represents methyl group or the like; R2 represents methoxy group or the like; and R3 represents carboxy group or the like.).

    摘要翻译： 本发明的目的是提供具有优异的脂肪组织减重作用，降血糖作用和降血脂作用的新型咔唑衍生物，溶剂合物或其药学上可接受的盐，其可用作脂肪的预防和/或治疗剂 肝脏，肥胖症，脂质代谢异常，内脏肥胖，糖尿病，高脂血症，葡萄糖耐量降低，高血压，非酒精性脂肪性肝病，非酒精性脂肪性肝炎等。 上述目的可以通过其咔唑衍生物，溶剂化物或其药学上可接受的盐来实现，其中咔唑衍生物由以下通式（I）表示：（式（I）中，环A表示苯基 X表示-O-等; Y表示= N-等; a和b表示亚甲基等; V和Z均表示-O-等; W表示C1-C10 其1或2个氢原子可被苯基或C1-C6烷基取代的亚烷基; 1,2-亚苯基; 1,3-环己基;等; R1代表甲基等; R2 表示甲氧基等; R3表示羧基等。

    Benzimidazole derivatives
    19.
    发明授权
    Benzimidazole derivatives 失效
    苯并咪唑衍生物

    公开(公告)号：US06884810B2

    公开(公告)日：2005-04-26

    申请号：US10380158

    申请日：2002-09-18

    申请人： Masaaki Nagasawa ,  Hiroyasu Nishioka ,  Kazuyasu Asami ,  Naoyoshi Miura ,  Yutaka Shinozaki ,  Hitoshi Morita

    发明人： Masaaki Nagasawa ,  Hiroyasu Nishioka ,  Kazuyasu Asami ,  Naoyoshi Miura ,  Yutaka Shinozaki ,  Hitoshi Morita

    IPC分类号： A61K31/4439 ,  A61P1/04 ,  C07D401/12

    CPC分类号： C07D401/12 ,  A61K31/4439

    摘要： A benzimidazole derivative of formula (1): (wherein R represents a hydrogen atom or a methoxy group, and n is 0 or 1) or a salt thereof; and a medicament containing the same. The compounds of the present invention, due to minimized difference in therapeutic effect between subjects, which difference would otherwise be derived from different CYP2C19 activity from subject to subject, ensure that all patients can enjoy proper therapeutic effects at the same dose of the drug. Also, the compounds of the invention have low risk of drug interaction caused by induction of CYP1A family member enzymes, as well as low risk of development of cancer, and thus is useful as a remedy for peptic ulcer, reliably providing therapeutic effects with safety.

    摘要翻译： 式（1）的苯并咪唑衍生物：其中R表示氢原子或甲氧基，n为0或1;或其盐; 和含有该药物的药物。 本发明的化合物由于受试者之间治疗效果的差异最小化，否则从受试者到受试者的不同CYP2C19活性的差异将确保所有患者在相同剂量的药物中可以获得适当的治疗效果。 此外，本发明的化合物由CYP1A家族成员酶的诱导引起的药物相互作用的风险低，并且癌症发展的风险低，因此可用作消化性溃疡的补救剂，可靠地提供安全的治疗效果。

    Colonic motor dysfunction remedies comprising aminothiazole derivatives as active ingredients
    20.
    发明申请
    Colonic motor dysfunction remedies comprising aminothiazole derivatives as active ingredients 有权
    包含氨基噻唑衍生物作为活性成分的结肠运动功能障碍疗法

    公开(公告)号：US20020051805A1

    公开(公告)日：2002-05-02

    申请号：US09853746

    申请日：2001-05-14

    申请人： ZERIA PHARMACEUTICAL CO., LTD.

    发明人： Shigeru Ueki ,  Yuko Hori ,  Yugo Matsunaga ,  Masaaki Nagasawa ,  Hiroyasu Nishioka ,  Masakazu Murata

    IPC分类号： A61F013/00

    CPC分类号： A61K31/426 ,  A61K31/381

    摘要： Remedies effective for the improvement of colonic motor dysfunction such as irritable bowel syndrome, constipation or intestinal atony without causing side effects on the central nerve system. These colonic motor dysfunction remedies comprise, as active ingredients, aminothiazole derivatives represented by the following formula (I) or a salt or hydrate thereof: 1 wherein R1, R2 and R3 may be the same or different and each independently represent a hydrogen atom or a hydroxyl, lower alkyl, lower alkoxy, amino, nitro or cyano group, R4 and R5 may be the same or different and each independently represent a hydrogen atom or a lower alkyl group, and n stands for an integer of from 2 to 4.

    摘要翻译： 治疗有助于改善结肠运动功能障碍，如肠易激综合征，便秘或肠痛，而不会对中枢神经系统造成副作用。 这些结肠运动障碍疗法包括作为活性成分的由下式（I）表示的氨基噻唑衍生物或其盐或水合物：其中R1，R2和R3可以相同或不同，并且各自独立地表示氢原子或羟基 ，低级烷基，低级烷氧基，氨基，硝基或氰基，R 4和R 5可以相同或不同，各自独立地表示氢原子或低级烷基，n表示2〜4的整数。